STOCK TITAN

Alvotech - ALVO STOCK NEWS

Welcome to our dedicated news page for Alvotech (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alvotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alvotech's position in the market.

Rhea-AI Summary
Alvotech receives complete response letter from FDA for AVT04 biosimilar candidate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Alvotech and Islandsbanki enter market making agreement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary
Alvotech and Kashiv Biosciences have entered into an exclusive licensing agreement for AVT23, a proposed biosimilar to Xolair. The agreement covers multiple major geographies and Alvotech will receive an exclusive license to commercialize AVT23. Kashiv will receive an upfront payment, milestone payments, and royalties. Global sales of Xolair were about $3.7 billion in the last twelve months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Summary
Alvotech's commercialization partner in Japan, Fuji Pharma, has received marketing approval for AVT04, a biosimilar to Stelara, from the Japanese Ministry of Health. AVT04 is the first biosimilar to Stelara to be approved for sale in global markets. Stelara's global sales reached over $10 billion for the twelve months preceding June 30, 2023. This approval allows Alvotech to increase patient access to vital biologic medicines in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
Rhea-AI Summary
Alvotech's resubmitted BLA for AVT02 accepted by FDA with a goal date for approval of February 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Summary
Alvotech announces participation in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
Rhea-AI Summary
Alvotech appoints Faysal Kalmoua as Chief Operating Officer and Hafrun Fridriksdottir steps down after resubmission of BLA for AVT02
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
management
-
Rhea-AI Summary
Alvotech reported $22.7 million in product revenue for H1 2023, compared to $3.9 million in H1 2022. Investors subscribed to $140 million in convertible bonds. Expanded partnerships with Teva Pharmaceuticals and Advanz Pharma. Settlement reached with Johnson & Johnson for US license entry date for AVT04 no later than Feb 21, 2025. Business update conference call on Aug 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
-
Rhea-AI Summary
Alvotech and Bioventure announce approval of AVT02 biosimilar in Egypt, increasing patient access to more affordable biologics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Rhea-AI Summary
Alvotech to release financial results for H1 2023 on August 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
Alvotech

Nasdaq:ALVO

ALVO Rankings

ALVO Stock Data

3.56B
83.10M
72.34%
6.97%
0.07%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Luxembourg
Luxembourg

About ALVO

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a